Third phase III trial of ethyl eicosapentaenoic acid [LAX 101; Miraxion] in patients with Huntington's disease.
Phase of Trial: Phase III
Latest Information Update: 08 Dec 2009
At a glance
- Drugs Ethyl eicosapentaenoic acid (Primary)
- Indications Huntington's disease
- Focus Registrational; Therapeutic Use
- Sponsors Amarin Corporation
- 26 Nov 2007 New trial record.